Global System Dynamics, Inc. Announces Sponsor Funding Of Additional One-Month Extension To Complete Its Initial Business Combination To January 9, 2024

Global System Dynamics, Inc. (NASDAQ:GSD) ("GSD" or the "Company") today announced that its sponsor, DarkPulse, Inc. (the "Sponsor"), has deposited an aggregate of $29,816.63 (representing approximately an additional

Global System Dynamics, Inc. (NASDAQ:GSD) (“GSD” or the “Company”) today announced that its sponsor, DarkPulse, Inc. (the “Sponsor”), has deposited an aggregate of $29,816.63 (representing approximately an additional $0.0625 per public share) into the Company’s trust account for the benefit of its valued public stockholders. This additional contribution enables the Company to extend the date by which the Company has to complete its initial business combination for an additional one-month extension from December 9, 2023 to January 9, 2024. Such contribution effectively increases the pro rata portion of the funds available in the Company’s trust account in the event of the consummation of an initial business combination, liquidation, or other redemption event, by $0.0625 per share.

 

Rick Iler, CFO of GSD, stated, “We are very excited to report once again that the Board of Directors has approved our Sponsor’s request for an additional one-month extension to complete the business combination. As such, our Sponsor has contributed approximately $29,816 in additional funds to the trust fund for the benefit of the stockholders of Global System Dynamics. These funds provide for an additional one-month extension which gives us additional time to advance our business combination efforts. Once completed, we remain confident that this transaction will create significant shareholder value.”

Today’s Sponsor contribution was funded as a non-interest bearing loan that will either be paid upon earlier of consummation of an initial business combination or the company’s liquidation, if there are funds available outside of the Company’s trust account.

Total
0
Shares
Related Posts
Read More

Gilead Announced Monday it Would Acquire Remaining Worldwide Rights of Trodelvy from Everest Medicines for $280M Upfront Plus Up to $175M in Milestones

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

GILD